• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

细胞内吉西他滨一磷酸水平可预测吉西他滨治疗膀胱癌患者的化疗疗效。

Intracellular Gemcitabine Monophosphate Levels Predict Chemotherapy Efficacy in Gemcitabine-Treated Patients with Bladder Cancer.

机构信息

Faculty of Biology and Biotechnology, Higher School of Economics, Moscow, Russia.

出版信息

Dokl Biochem Biophys. 2023 Dec;513(1):324-327. doi: 10.1134/S1607672923700503. Epub 2023 Sep 29.

DOI:10.1134/S1607672923700503
PMID:37768422
Abstract

Gemcitabine monophosphate (dFdCMP), one of the intracellular forms of phosphorylated gemcitabine, determines its antitumor activity. A pharmaco-molecular model for determining relative gemcitabine monophosphate level based on the assessment of the activity of ENT1 and ENT2 channels as well as dCK and CDA enzymes in tumor tissue was developed. Relative gemcitabine monophosphate level is a more relevant predictive factor of gemcitabine resistance of bladder cancer as compared with the expression of individual markers related to dFdCMP formation.

摘要

单磷酸吉西他滨（dFdCMP）是吉西他滨的一种细胞内磷酸化形式，决定了其抗肿瘤活性。开发了一种基于肿瘤组织中 ENT1 和 ENT2 通道以及 dCK 和 CDA 酶活性评估来确定相对单磷酸吉西他滨水平的药物分子模型。与与 dFdCMP 形成相关的单个标志物的表达相比，相对单磷酸吉西他滨水平是膀胱癌对吉西他滨耐药性的更相关的预测因子。

相似文献

1
Intracellular Gemcitabine Monophosphate Levels Predict Chemotherapy Efficacy in Gemcitabine-Treated Patients with Bladder Cancer.细胞内吉西他滨一磷酸水平可预测吉西他滨治疗膀胱癌患者的化疗疗效。
Dokl Biochem Biophys. 2023 Dec;513(1):324-327. doi: 10.1134/S1607672923700503. Epub 2023 Sep 29.
2
HYAL4-V1/Chondroitinase (Chase) Drives Gemcitabine Resistance and Predicts Chemotherapy Failure in Patients with Bladder Cancer.HYAL4-V1/Chondroitinase (Chase) 驱动吉西他滨耐药并预测膀胱癌患者化疗失败。
Clin Cancer Res. 2021 Aug 1;27(15):4410-4421. doi: 10.1158/1078-0432.CCR-21-0422. Epub 2021 May 24.
3
Gemcitabine in the treatment of bladder cancer.吉西他滨治疗膀胱癌
Expert Opin Pharmacother. 2000 Mar;1(3):547-53. doi: 10.1517/14656566.1.3.547.
4
Disrupted plasma membrane localization of equilibrative nucleoside transporter 2 in the chemoresistance of human pancreatic cells to gemcitabine (dFdCyd).在吉西他滨（dFdCyd）耐药的人胰腺细胞中，核苷转运蛋白 2 的质膜定位被打乱。
Cancer Sci. 2011 Mar;102(3):622-9. doi: 10.1111/j.1349-7006.2010.01837.x. Epub 2011 Jan 20.
5
Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity.治疗前脱氧胞苷激酶水平可预测吉西他滨的体内敏感性。
Mol Cancer Ther. 2002 Apr;1(6):371-6.
6
Increased expression of transcription factor TFAP2α correlates with chemosensitivity in advanced bladder cancer.转录因子 TFAP2α 的表达增加与晚期膀胱癌的化疗敏感性相关。
BMC Cancer. 2011 Apr 14;11:135. doi: 10.1186/1471-2407-11-135.
7
Functional p53 mutation as a molecular determinant of paclitaxel and gemcitabine susceptibility in human bladder cancer.功能性p53突变作为人膀胱癌中紫杉醇和吉西他滨敏感性的分子决定因素。
J Urol. 2001 Aug;166(2):482-7.
8
β-Arrestins Regulate Stem Cell-Like Phenotype and Response to Chemotherapy in Bladder Cancer.β-arrestins 调节膀胱癌中的干细胞样表型和化疗反应。
Mol Cancer Ther. 2019 Apr;18(4):801-811. doi: 10.1158/1535-7163.MCT-18-1167. Epub 2019 Feb 20.
9
Quantitative Targeted Proteomics of Pancreatic Cancer: Deoxycytidine Kinase Protein Level Correlates to Progression-Free Survival of Patients Receiving Gemcitabine Treatment.胰腺癌的定量靶向蛋白质组学：脱氧胞苷激酶蛋白水平与接受吉西他滨治疗患者的无进展生存期相关。
Mol Pharm. 2015 Sep 8;12(9):3282-91. doi: 10.1021/acs.molpharmaceut.5b00282. Epub 2015 Aug 25.
10
Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma.吉西他滨的转运和代谢蛋白水平可预测接受吉西他滨治疗的胰腺腺癌患者的生存时间。
Gastroenterology. 2012 Sep;143(3):664-674.e6. doi: 10.1053/j.gastro.2012.06.006. Epub 2012 Jun 13.

本文引用的文献

1
Genome-Wide CRISPR Screening Identifies DCK and CCNL1 as Genes That Contribute to Gemcitabine Resistance in Pancreatic Cancer.全基因组CRISPR筛选确定DCK和CCNL1为导致胰腺癌吉西他滨耐药的基因。
Cancers (Basel). 2022 Jun 27;14(13):3152. doi: 10.3390/cancers14133152.
2
Bladder Cancer: A Review.膀胱癌：综述。
JAMA. 2020 Nov 17;324(19):1980-1991. doi: 10.1001/jama.2020.17598.
3
Mechanistic Multiscale Pharmacokinetic Model for the Anticancer Drug 2',2'-difluorodeoxycytidine (Gemcitabine) in Pancreatic Cancer.胰腺癌中抗癌药物2',2'-二氟脱氧胞苷（吉西他滨）的多尺度药代动力学机制模型
Clin Transl Sci. 2020 May;13(3):608-617. doi: 10.1111/cts.12747. Epub 2020 Mar 3.
4
SciPy 1.0: fundamental algorithms for scientific computing in Python.SciPy 1.0：Python 中的科学计算基础算法。
Nat Methods. 2020 Mar;17(3):261-272. doi: 10.1038/s41592-019-0686-2. Epub 2020 Feb 3.
5
Messenger-RNA Expression of Five Gemcitabine Sensitivity-related Genes Predicting Outcome in Advanced-stage Non-small Cell Lung Cancer.吉西他滨敏感性相关五个基因的信使 RNA 表达预测晚期非小细胞肺癌的预后。
Anticancer Res. 2020 Feb;40(2):901-913. doi: 10.21873/anticanres.14023.
6
Phase I study of gemcitabine-cisplatin versus pemetrexed cisplatin for patients with advanced or metastatic bladder cancer.吉西他滨-顺铂对比培美曲塞顺铂用于晚期或转移性膀胱癌患者的I期研究
J BUON. 2018 Mar-Apr;23(2):475-481.
7
Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer.起源细胞模式主导了 33 种癌症类型的 10000 个肿瘤的分子分类。
Cell. 2018 Apr 5;173(2):291-304.e6. doi: 10.1016/j.cell.2018.03.022.
8
Intracellular pharmacokinetics of gemcitabine, its deaminated metabolite 2',2'-difluorodeoxyuridine and their nucleotides.吉西他滨、其脱氨酶代谢产物 2',2'-二氟脱氧尿苷及其核苷酸的细胞内药代动力学。
Br J Clin Pharmacol. 2018 Jun;84(6):1279-1289. doi: 10.1111/bcp.13557. Epub 2018 Apr 16.
9
Predicting tumour growth and its impact on survival in gemcitabine-treated patients with advanced pancreatic cancer.预测吉西他滨治疗晚期胰腺癌患者的肿瘤生长及其对生存的影响。
Eur J Pharm Sci. 2018 Mar 30;115:296-303. doi: 10.1016/j.ejps.2018.01.033. Epub 2018 Jan 31.
10
Low expression of equilibrative nucleoside transporter 1 is associated with poor prognosis in chemotherapy-naïve pT2 gallbladder adenocarcinoma patients.平衡核苷转运体1低表达与未经化疗的pT2胆囊腺癌患者预后不良相关。
Histopathology. 2016 Apr;68(5):722-8. doi: 10.1111/his.12805. Epub 2015 Oct 21.